Neonatal surfactant therapy beyond respiratory distress syndrome [0.03%]
用于治疗新生儿呼吸窘迫综合征以外疾病的表面活性物质疗法
Peter A Dargaville,Egbert Herting,Roger F Soll
Peter A Dargaville
Whilst exogenous surfactant therapy is central to the management of newborn infants with respiratory distress syndrome, its use in other neonatal lung diseases remains inconsistent and controversial. Here we discuss the evidence and experie...
Arun Sett,Charles C Roehr,Brett J Manley
Arun Sett
Drug delivery using a surfactant vehicle has the potential to prevent systemic side effects by delivering therapeutic agents directly to the respiratory system. The inherent chemical properties of surfactant allows it to readily distribute ...
Synthetic surfactants [0.03%]
合成表面活性剂
Fernando Moya,Tore Curstedt,Jan Johansson et al.
Fernando Moya et al.
Towards personalized therapies for genetic disorders of surfactant dysfunction [0.03%]
向遗传性肺表面活性剂功能障碍的个性化治疗迈进
Maureen Peers de Nieuwburgh,Jennifer A Wambach,Matthias Griese et al.
Maureen Peers de Nieuwburgh et al.
Genetic disorders of surfactant dysfunction are a rare cause of chronic, progressive or refractory respiratory failure in term and preterm infants. This review explores genetic mechanisms underpinning surfactant dysfunction, highlighting sp...
Sandy Kirolos,Gemma Edwards,Joyce O&#x;Shea
Sandy Kirolos
Endotracheal intubation is a life-saving procedure for many newborns. Historically, it has been achieved by obtaining an airway view through the mouth via direct laryngoscopy. It is a skill that takes time and practice to achieve proficienc...
M Silena Mosquera,Sara Yuter,Alan W Flake
M Silena Mosquera
The ex-utero intrapartum treatment (EXIT) procedure was originally developed to reverse tracheal occlusion in fetuses with severe congenital diaphragmatic hernia that underwent fetal tracheal occlusion. The EXIT procedure has since been app...
Anton H van Kaam
Anton H van Kaam
Lucy E Geraghty,Eoin Ó Curraín,Lisa K McCarthy et al.
Lucy E Geraghty et al.
Interest in 'resurrecting' the lifeless by supporting breathing has been described since ancient times. For centuries, methods of resuscitating animals, then humans and specifically the 'lifeless' neonate were debated and discussed. Over ti...
Matteo Bruschettini
Matteo Bruschettini
This chapter focuses on the pharmacological management of newborn infants in the peri-extubation period to reduce the risk of re-intubation and prolonged mechanical ventilation. Drugs used to promote respiratory drive, reduce the risk of ap...
Historical perspective on surfactant therapy: Transforming hyaline membrane disease to respiratory distress syndrome [0.03%]
_surfactant治疗的历史回顾：从透明膜病到呼吸窘迫综合征_
Mikko Hallman,Egbert Herting
Mikko Hallman
Lung surfactant is the first drug so far designed for the special needs of the newborn. In 1929, Von Neergard described lung hysteresis and proposed the role of surface forces. In 1955-1956, Pattle and Clements found direct evidence of lung...